Ask Warren

OSCOTECInc

039200 · KOSDAQ · ₩039200 · 오스코텍

₩35,900▼ ₩100 (0.28%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −11.03%
Market cap
₩1.4T
Enterprise value
₩1.4T
P/E
14.6×
P/B
6.4×
Dividend yield
0.0%
ROE
43.6%
Net margin
65.2%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−45.6% from the high

₩27,300Today: ₩35,700 – ₩37,450₩66,000

Returns

  • 1W−4.3%
  • 1M+0.3%
  • 3M+18.7%
  • 6M−33.4%
  • YTD−20.6%
  • 1Y−11.0%
Volume today
123,683
1.0× the 20-day average
Traded today
₩4.5B
Listed shares
38,258,176
EPS (12 months)
₩2,459
Earnings yield 6.8%
SellBuy
AI research · InitiationOSCOTEC: Profits Turn Sharply Positive Since 2024 While Shares Trade Well Below 52-Week HighThe filed data shows a clear break from loss-making years to high margins and strong cash flow, with low debt.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

45Normal
  • BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: One positive headline about a large licensing deal, with no further detail. Community: 0 bullish, 0 bearish posts this week.
  • MomentumFlat-0.8% over the last month; the price is below its 20-day average.
  • News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩465M at the close (9.6% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 21 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 30.2% of trading value and pointed the same way 18 of 21 times.

  • 2× KODEX KOSDAQ150 Leverage ₩380M
  • 2× TIGER KOSDAQ150 Leverage ₩45M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩26M
  • 2× RISE KOSDAQ150 Futures Leverage ₩7.9M
  • 2× KIWOOM KOSDAQ150 Futures Leverage ₩2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 35,750

Basis −0.42% · implied rate −9.6%

Open interest 370 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

OSCOTECInc stock overview

OSCOTECInc (오스코텍, KRX: 039200) is listed on KOSDAQ, in the Biotech & Pharma sector. This Korean company is a research-focused drug discovery and biotech firm that has concentrated on synthetic small-molecule drugs, including treatments for arthritis and cancer. Its shares closed at ₩35,900 on Oct 27, 2026, down 0.28% on the day, giving it a market value of ₩1.4T.

Key facts

Market cap
₩1.4T
Sector
Biotech & Pharma
Latest price change
−0.28%
As of
Oct 27, 2026
Main business
This Korean company is a research-focused drug discovery and biotech firm that has concentrated on synthetic small-molecule drugs, including treatments for arthritis and cancer.

Quick answers about OSCOTECInc

What does OSCOTECInc do?
This Korean company is a research-focused drug discovery and biotech firm that has concentrated on synthetic small-molecule drugs, including treatments for arthritis and cancer. Its business also includes dental bone grafting materials and dental barrier membranes, sold mainly to dentists and dental distributors in Korea, and functional materials used mainly as ingredients in health functional foods, with exports to Japan. The company's largest revenue in its latest year came from technology transfer and royalty income from licensing a targeted lung cancer drug to a Korean pharmaceutical firm.
What is the market cap of OSCOTECInc?
The market capitalisation of OSCOTECInc was ₩1.4T at the close on Oct 27, 2026.
Who are the largest shareholders of OSCOTECInc?
According to the latest official filings, the largest reported holders are Kim Seong-yeon (22.25%, as of Sep 18, 2026); Kim Jung-geun (12.67%, as of Apr 18, 2025); Tiger Asset Management Discretionary Investment (5.09%, as of May 22, 2026).
When is the next earnings report from OSCOTECInc?
Korean companies rarely announce results dates in advance. Based on when OSCOTECInc filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 14, 2026.
Does the National Pension Service own OSCOTECInc?
Yes. The National Pension Service held 3.87% of OSCOTECInc shares as of Jan 2, 2026.

Company profile

This Korean company is a research-focused drug discovery and biotech firm that has concentrated on synthetic small-molecule drugs, including treatments for arthritis and cancer. Its business also includes dental bone grafting materials and dental barrier membranes, sold mainly to dentists and dental distributors in Korea, and functional materials used mainly as ingredients in health functional foods, with exports to Japan. The company's largest revenue in its latest year came from technology transfer and royalty income from licensing a targeted lung cancer drug to a Korean pharmaceutical firm.

Written by AI from the company's latest annual report.

Korean name
오스코텍
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
윤태영,이상현
Founded
Dec 1998
Listed
Jan 2007
Listed shares
38,258,176
Fiscal year ends
Month 12
Website
www.oscotec.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: OSCOTECInc / 오스코텍 / 039200 / KRX:039200

Source: KRX statistical information